Ward Richard J, Pediani John D, Marsango Sara, Jolly Richard, Stoneman Michael R, Biener Gabriel, Handel Tracy M, Raicu Valerică, Milligan Graeme
Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.
Physics Department, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
J Biol Chem. 2021 Jan-Jun;296:100139. doi: 10.1074/jbc.RA120.016612. Epub 2020 Dec 6.
CXCR4, a member of the family of chemokine-activated G protein-coupled receptors, is widely expressed in immune response cells. It is involved in both cancer development and progression as well as viral infection, notably by HIV-1. A variety of methods, including structural information, have suggested that the receptor may exist as a dimer or an oligomer. However, the mechanistic details surrounding receptor oligomerization and its potential dynamic regulation remain unclear. Using both biochemical and biophysical means, we confirm that CXCR4 can exist as a mixture of monomers, dimers, and higher-order oligomers in cell membranes and show that oligomeric structure becomes more complex as receptor expression levels increase. Mutations of CXCR4 residues located at a putative dimerization interface result in monomerization of the receptor. Additionally, binding of the CXCR4 antagonist IT1t-a small drug-like isothiourea derivative-rapidly destabilizes the oligomeric structure, whereas AMD3100, another well-characterized CXCR4 antagonist, does not. Although a mutation that regulates constitutive activity of CXCR4 also results in monomerization of the receptor, binding of IT1t to this variant promotes receptor dimerization. These results provide novel insights into the basal organization of CXCR4 and how antagonist ligands of different chemotypes differentially regulate its oligomerization state.
CXCR4是趋化因子激活的G蛋白偶联受体家族的一员,在免疫反应细胞中广泛表达。它参与癌症的发生和发展以及病毒感染,尤其是HIV-1感染。包括结构信息在内的多种方法表明,该受体可能以二聚体或寡聚体形式存在。然而,围绕受体寡聚化及其潜在动态调节的机制细节仍不清楚。我们通过生化和生物物理手段证实,CXCR4在细胞膜中可以以单体、二聚体和高阶寡聚体的混合物形式存在,并表明随着受体表达水平的增加,寡聚体结构变得更加复杂。位于假定二聚化界面的CXCR4残基发生突变会导致受体单体化。此外,CXCR4拮抗剂IT1t(一种类似药物的异硫脲衍生物)的结合会迅速破坏寡聚体结构,而另一种特征明确的CXCR4拮抗剂AMD3100则不会。虽然调节CXCR4组成型活性的突变也会导致受体单体化,但IT1t与该变体的结合会促进受体二聚化。这些结果为CXCR4的基础组织以及不同化学类型的拮抗剂配体如何差异调节其寡聚化状态提供了新的见解。